The Medtronic Resting Heart System is intended for use in surgical procedures requiring extracorporeal gas exchange, circulatory support, and thermal regulation. This device is indicated for use in procedures requiring blood flow rate of 1 to 6 liters/min and lasting up to six hours. The system is indicated for use only with the Bio-Console.

Device Description

The Medtronic Resting Heart System is a low prime volume alternative to existing Cardiopulmonary Bypass (CPB) perfusion circuit. The system is used for patient support during cardiopulmonary procedures lasting up to 6 hours. The System consists of the Medtronic Resting Heart System Controller for Active Air Removal and the Medtronic Resting Heart Disposable Module. The venous return portion of the CPB circuit is connected to a Venous Air Removal Device (VARD) that is equipped with an automated air removal system connected to the vent port on the device. The VARD is an AFFINITY Arterial Filter (38 micron) moved to the venous side of the circuit and equipped with ultrasonic crystals that sense the liquid level in the filter. The VARD replaces the Affinity Cardiotomy Venous Reservoir (CVR) or the Affinity Venous Reservoir Bag (VRB) that is normally used to remove air from the venous blood entering the CPB circuit.

AI/ML Overview

The provided text is a 510(k) summary for the Medtronic Resting Heart System, a medical device used in cardiopulmonary bypass surgery. It describes the device, its intended use, and compares it to predicate devices to establish substantial equivalence.

However, the document does not contain information related to specific acceptance criteria as quantitative performance metrics (e.g., sensitivity, specificity, accuracy, or specific physiological parameters with thresholds) for an AI/algorithm-driven device, nor does it describe a study in the context of evaluating such an algorithm's performance against ground truth.

Instead, the performance data mentioned refers to engineering and physiological performance of the hardware components of the system (e.g., "Air Handling capabilities, blood trauma, pressure drops") and "Software Verification and Validation" for the Active Air Removal Controller. This type of documentation is typical for hardware devices and their embedded software, rather than for advanced AI/ML algorithms requiring extensive clinical validation against a gold standard for diagnostic or predictive accuracy.

Therefore, I cannot populate the table or answer most of the questions as the requested information (related to AI/algorithm performance, ground truth, expert consensus, sample sizes for test/training sets in an AI context, etc.) is not present in the provided text.

Based on the nature of the device (Cardiopulmonary Bypass System) and the time of the submission (2003), it's highly unlikely that it involved an AI-driven component as understood in the context of the questions asked. The "Active Air Removal Controller" likely refers to a rule-based or control-system algorithm embedded in the device, not a machine learning model.

If you can provide a document that specifically details the validation of an AI/ML algorithm within a medical device, I would be happy to help.

Summary

{0}------------------------------------------------

AUG 2 9 2003

Medtronic Resting Heart System 510(k) Submi

APPENDIX II

510(k) Summary

Medtronic Resting Heart System

(As required by 21CFR 807.92)

Submitter Information A.

Submitter's Name:	Medtronic Perfusion Systems
Address:	7611 Northland Drive N
	Minneapolis, Minnesota 55428-1088 U.S.A.
Telephone Number:	763.391.9000
Contact Person:	Preeti Jain
Date Submission Prepared:	May 30, 2003

B. Device Information

Device Trade Name:	Medtronic Resting Heart System
Common or usual Name:	Cardiopulmonary Bypass Surgery Circuit with Active AirRemoval, Oxygenator, Centrifugal blood Pump, ArterialFilter, flow probe, tri-optic measurement cell, tubings andconnectors, holding bag.
Classification Name:	For the new/changed components:Cardiopulmonary bypass blood reservoir,Cardiopulmonary bypass adaptors, fittings, manifold,
	For the unchanged components:
	Cardiopulmonary Bypass Oxygenator,
	Cardiopulmonary bypass heat exchanger,
	Cardiopulmonary Bypass blood pump (Non Roller type),
	Cardiopulmonary bypass arterial line blood filter,
	Cardiopulmonary bypass tubing,
	Cardiopulmonary bypass inline gas sensor,
	Cardiopulmonary bypass pump speed control

{1}------------------------------------------------

Predicate Devices(For new/changed components):

	1. AFFINITY® Venous Reservoir Bag (K935717)
	2. Carmeda™ Coated Tubings and Connectors (K891687)
	3. Medtronic Overpressure/Vacuum Relief Valve(K953564)
	4. CardioVentions CORx System (K012325)
Device Description:	The Medtronic Resting Heart System is a low primevolume alternative to existing Cardiopulmonary Bypass(CPB) perfusion circuit. The system is used for patientsupport during cardiopulmonary procedures lasting up to 6hours. The System consists of the Medtronic Resting HeartSystem Controller for Active Air Removal and theMedtronic Resting Heart Disposable Module
	The venous return portion of the CPB circuit is connectedto a Venous Air Removal Device (VARD) that is equippedwith an automated air removal system connected to thevent port on the device. The VARD is an AFFINITYArterial Filter (38 micron) moved to the venous side of thecircuit and equipped with ultrasonic crystals that sense theliquid level in the filter. The VARD replaces the Affinity™Cardiotomy Venous Reservoir (CVR) or the Affinity™Venous Reservoir Bag (VRB) that is normally used toremove air from the venous blood entering the CPB circuit.
Indications for Use:	The Medtronic Resting Heart System is intended for usein surgical procedures requiring extracorporeal gasexchange, circulatory support, and thermal regulation. Thisdevice is indicated for use in procedures requiring bloodflow rate of 1 to 6 liters/min and lasting up to six hours.The system is indicated for use only with the Bio-Console

C. Comparison of Required Technological Characteristics

Medtronic Resting Heart System is a system comprised of standard components of an extracorporeal circuit for use during cardiopulmonary bypass. The system has the same technological characteristics as a traditional circuit and the single components have the same technological characteristics as the predicate.

{2}------------------------------------------------

D. Performance Data

Performance data, such as, Air Handling capabilities, blood trauma, pressure drops have been provided in the 510(k) submission to show equivalence of the Medtronic Resting Heart System to a standard extracorporeal circuit. In addition comprehensive testing has been completed on the Active Air Removal Controller including performance and Software Verification and Validation.

Conclusion

Medtronic Resting Heart System is substantially equivalent to the noted predicate device based on the similarities of technological characteristics, indications for use and the results of performance comparative testing.

{3}------------------------------------------------

Public Health Service

Image /page/3/Picture/2 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. In the center of the seal is an abstract image of an eagle with its wings spread.

AUG 2 9 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Medtronic Perfusion Systems c/o Ms. Preeti Jain 7611 Northland Drive Minneapolis, MN 55428

Re: K031700

Medtronic Resting Heart™ System Regulation Number: 21 CFR 870.4290, 870.4400 Regulation Name: Cardiopulmonary Bypass Blood Reservoir and Bypass Adaptor, Stopcock, Manifold, or Fitting Regulatory Class: Class II (two) Product Code: DTN, DTL Dated: May 30, 2003 Received: June 2, 2003

Dear Ms. Jain:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{4}------------------------------------------------

Page 2 - Ms. Preeti Jain

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Jhsa DAz fr

Bram D. Zuckerma Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Medtronic Resting Heart System 510(k) Submission

APPENDIX IV

Indications for Use Statement

Page	1 of 1
510(k) Number (if known):	K031700
Device Name:	Medtronic Resting Heart System

Indications for Use:

ﻜ

Prescription Use (Per 21 CFR 801.109)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)	[Signature]
	[Signature]
Division of Cardiovascular Devices
510(k) Number	K031700

Prescription Use(Per 21 CFR 801.109)	X	OR	Over-The-Counter Use(Optional Format 1-2-96)	_
------------------------------------------	---	----	--------------------------------------------------	---

Regulation Number and Section

§ 870.4400 Cardiopulmonary bypass blood reservoir.

(a)
Identification. A cardiopulmonary bypass blood reservoir is a device used in conjunction with short-term extracorporeal circulation devices to hold a reserve supply of blood in the bypass circulation.(b)
Classification. Class II (special controls), except that a reservoir that contains a defoamer or filter is classified into the same class as the defoamer or filter. The device, when it is a cardiopulmonary bypass blood reservoir that does not contain defoamers or blood filters, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.